 Connection
Sandra Luna-Fineman to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications Sandra Luna-Fineman has written about Antineoplastic Combined Chemotherapy Protocols.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.103 |
|
|
|
-
Luna-Fineman S, Chantada G, Alejos A, Amador G, Barnoya M, Castellanos ME, Fu L, Fuentes-Alabi S, Girón V, Goenz MA, Maldonado C, Méndez G, Morales RA, Ortiz R, Sanchez G, Wilson M, Rodríguez-Galindo C. Delayed Enucleation With Neoadjuvant Chemotherapy in Advanced Intraocular Unilateral Retinoblastoma: AHOPCA II, a Prospective, Multi-Institutional Protocol in Central America. J Clin Oncol. 2019 11 01; 37(31):2875-2882.
Score: 0.303
-
Luna-Fineman S, Barnoya M, Bonilla M, Fu L, Baez F, Rodríguez-Galindo C. Retinoblastoma in Central America: report from the Central American Association of Pediatric Hematology Oncology (AHOPCA). Pediatr Blood Cancer. 2012 Apr; 58(4):545-50.
Score: 0.174
-
Flerlage JE, Feraco AM, Zhou Y, Zheng Y, Liang J, Lucas JT, Friedmann AM, Weinstein HJ, Yock TI, Shulkin B, Kaste SC, Marks LJ, Ehrhardt MJ, Dixon SB, Howard S, de Alarcon P, Luna-Fineman S, Geddis A, Larsen EC, Marcus K, Billett AL, Donaldson SS, Hudson MM, Metzger ML, Krasin MJ, Link MP. Dose-dense chemotherapy enables elimination of RT for the majority of low-risk pediatric Hodgkin lymphomas: PHC study HOD08. Blood. 2026 Mar 19; 147(12):1289-1301.
Score: 0.119
-
Velasquez-Herrera T, Valverde P, Fuentes S, Peña A, Ortiz R, Calderon P, Montero M, Gattuso G, Blanco J, Arreola M, Fernandez-Pineda I, Metzger M, Luna-Fineman S, Wilimas J, Spreafico F. Second Generation of AHOPCA (Asociación de Hemato-Oncología Pediátrica de Centro América) Treatment Guidelines for Wilms Tumor: A Report of Outcomes. Pediatr Blood Cancer. 2026 Feb; 73(2):e32148.
Score: 0.116
-
Luna-Fineman S, Castellanos M, Metzger ML, Baez LF, Peña Hernandez A, Bonilla M, Fuentes-Alabi S, Nieves R, Blanco J, Rossi E, Devidas M, Chen Y, Arreola M, de Alarcon PA. Treatment of high-risk Hodgkin lymphoma with a modified Stanford V regimen in the AHOPCA: Substituting chemotherapy agents and hampered outcomes. Pediatr Blood Cancer. 2024 Feb; 71(2):e30792.
Score: 0.101
-
Graff Z, Giron V, Miller K, Pixtun D, Alejos A, Luna-Fineman S. Toxicity and feasibility of vincristine, etoposide, and carboplatin alternating with vincristine, doxorubicin, and cyclophosphamide in children with advanced retinoblastoma in Guatemala. Pediatr Blood Cancer. 2023 07; 70(7):e30392.
Score: 0.097
-
Metzger ML, Link MP, Billett AL, Flerlage J, Lucas JT, Mandrell BN, Ehrhardt MJ, Bhakta N, Yock TI, Friedmann AM, de Alarcon P, Luna-Fineman S, Larsen E, Kaste SC, Shulkin B, Lu Z, Li C, Hiniker SM, Donaldson SS, Hudson MM, Krasin MJ. Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation. J Clin Oncol. 2021 07 10; 39(20):2276-2283.
Score: 0.084
-
Quackenbush KE, Luna-Fineman S, Magee JF, Gundogan M, Golobi M, Irie T, Fernandez CV. Neuroblastoma involvement of the falx cerebri. Pediatr Blood Cancer. 2009 Dec 15; 53(7):1337-9.
Score: 0.039
-
Antillon F, Castellanos M, Valverde P, Luna-Fineman S, Garrido C, Serrato T, Rodriguez-Galindo C, Casanova M, Ferrari A. Treating Pediatric soft tissue sarcomas in a country with limited resources: the experience of the Unidad Nacional de Oncologia Pediatrica in Guatemala. Pediatr Blood Cancer. 2008 Dec; 51(6):760-4.
Score: 0.036
-
Lange BJ, Smith FO, Feusner J, Barnard DR, Dinndorf P, Feig S, Heerema NA, Arndt C, Arceci RJ, Seibel N, Weiman M, Dusenbery K, Shannon K, Luna-Fineman S, Gerbing RB, Alonzo TA. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood. 2008 Feb 01; 111(3):1044-53.
Score: 0.033
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|